Literature DB >> 80223

Carcinoembryonic antigen in hepatocellular cancer.

G M Macnab, J M Urbanowicz, M C Kew.   

Abstract

Serum carcinoembryonic antigen (CEA) concentrations were found to be raised in 28 of 72 black patients (39%) with hepatocellular cancer (HCC). The degree of elevation was slight or moderate, except in 3 patients in whom values greater than 20 ng/ml were recorded. No significant correlation could be demonstrated in individual patients between the serum CEA concentration and various tests of liver function. The mean CEA value in the patients with cirrhosis in the non-tumorous liver was slightly higher than that in those without cirrhosis, but the difference did not reach statistical significance. There was no correlation between serum CEA and alpha-foetoprotein (AFP) levels.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 80223      PMCID: PMC2009669          DOI: 10.1038/bjc.1978.162

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  The hepatic clearance of circulating native and asialo carcinoembronic antigen by the rat.

Authors:  P Thomas; D A Hems
Journal:  Biochem Biophys Res Commun       Date:  1975-12-01       Impact factor: 3.575

Review 2.  The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins.

Authors:  G Ashwell; A G Morell
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1974

3.  Carcinoembryonic antigen(s) in liver disease. I. Clinical and morphological studies.

Authors:  T Moore; P Dhar; N Zamcheck; A Keeley; L Gottlieb; H Z Kupchik
Journal:  Gastroenterology       Date:  1972-07       Impact factor: 22.682

4.  Carcinoembryonic antigenic activity of tissue extracts: a quantitative study of malignant and benign neoplasms, cirrhotic liver, normal adult and fetal organs.

Authors:  S K Khoo; N L Warner; J T Lie; I R Mackay
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

5.  Demonstration of an antigen common to several varieties of neoplasia.

Authors:  P Lo Gerfo; J Krupey; H J Hansen
Journal:  N Engl J Med       Date:  1971-07-15       Impact factor: 91.245

Review 6.  Alpha-fetoprotein in primary liver cancer and other diseases.

Authors:  M Kew
Journal:  Gut       Date:  1974-10       Impact factor: 23.059

7.  Studies of carcino-fetal proteins. 3. Development of a radioimmunoassay for -fetoprotein. Demonstration of -fetoprotein in serum of healthy human adults.

Authors:  E Ruoslahti; M Seppälä
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

8.  The value of carcinoembryonic antigen (CEA) as an adjunct to the radiological colon examination in the diagnosis of malignancy.

Authors:  W H McCartney; P B Hoffer
Journal:  Radiology       Date:  1974-02       Impact factor: 11.105

9.  Localization by immunoperoxidase and estimation by radioimmunoassay of carcinoembryonic antigen in colonic polyps.

Authors:  R M Sharkey; P F Hagihara; D M Goldenberg
Journal:  Br J Cancer       Date:  1977-02       Impact factor: 7.640

10.  Alpha-foetoprotein and carcinoembryonic antigen in germ cell neoplasms.

Authors:  A Talerman; W B van der Pompe; W G Haije; L Baggerman; H M Boekestein-Tjahjadi
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

View more
  9 in total

1.  Fibrolamellar carcinoma of the liver. Review of three cases and the presentation of a characteristic set of tumor markers defining this tumor.

Authors:  D H Teitelbaum; S Tuttle; L C Carey; K P Clausen
Journal:  Ann Surg       Date:  1985-07       Impact factor: 12.969

2.  Hepatocellular carcinoma producing carcinoembryonic antigen.

Authors:  M Maeda; S Tozuka; M Kanayama; T Uchida
Journal:  Dig Dis Sci       Date:  1988-12       Impact factor: 3.199

3.  Myrtenal, a natural monoterpene, down-regulates TNF-α expression and suppresses carcinogen-induced hepatocellular carcinoma in rats.

Authors:  Lingaiah Hari Babu; Srinivasan Perumal; Maruthaiveeran Periyasamy Balasubramanian
Journal:  Mol Cell Biochem       Date:  2012-07-05       Impact factor: 3.396

4.  Morin augments anticarcinogenic and antiproliferative efficacy against 7,12-dimethylbenz(a)-anthracene induced experimental mammary carcinogenesis.

Authors:  Ramadass Nandhakumar; Kombiyil Salini; Sivasithambaram Niranjali Devaraj
Journal:  Mol Cell Biochem       Date:  2012-02-19       Impact factor: 3.396

5.  Antioxidant and anticancer efficacy of hesperidin in benzo(a)pyrene induced lung carcinogenesis in mice.

Authors:  Sattu Kamaraj; Gopalakrishnan Ramakrishnan; Pandi Anandakumar; Sundaram Jagan; Thiruvengadam Devaki
Journal:  Invest New Drugs       Date:  2008-08-13       Impact factor: 3.850

6.  Fisetin modulates mitochondrial enzymes and apoptotic signals in benzo(a)pyrene-induced lung cancer.

Authors:  Nagaiya Ravichandran; Gopal Suresh; Balasubramanian Ramesh; Ramar Manikandan; Young Whan Choi; Ganesan Vijaiyan Siva
Journal:  Mol Cell Biochem       Date:  2014-02-05       Impact factor: 3.396

7.  Chemopreventive effect of bacoside A on N-nitrosodiethylamine-induced hepatocarcinogenesis in rats.

Authors:  Panneerselvam Janani; Kanakarajan Sivakumari; Arumugam Geetha; Baskaran Ravisankar; Chandrakesan Parthasarathy
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-15       Impact factor: 4.553

8.  Carvacrol modulates instability of xenobiotic metabolizing enzymes and downregulates the expressions of PCNA, MMP-2, and MMP-9 during diethylnitrosamine-induced hepatocarcinogenesis in rats.

Authors:  Jayakumar Subramaniyan; Gokuladhas Krishnan; Rajan Balan; Divya Mgj; Elamaran Ramasamy; Shenbhagaraman Ramalingam; Ramakrishnan Veerabathiran; Premkumar Thandavamoorthy; Gopi Krishnan Mani; Devaki Thiruvengadam
Journal:  Mol Cell Biochem       Date:  2014-06-01       Impact factor: 3.396

9.  Chemopreventive Activity of Honokiol against 7, 12 - Dimethylbenz[a]anthracene-Induced Mammary Cancer in Female Sprague Dawley Rats.

Authors:  Zhenyu Wang; Xingyi Zhang
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.